Takuya Fujimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takuya Fujimoto has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Ikuo Fujita
Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, 673-8558, Japan
4 shared publicationsShunsuke Yahiro
Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi, 673-8558, Japan
4 shared publicationsHiroki Tanaka
Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
3 shared publicationsHitomi Hara
Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan
3 shared publicationsMinoru Suzuki
Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, 590-0494, Japan
3 shared publicationsRyosuke Kuroda
Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan
3 shared publications
Latest Publications
- 31 May 2025
- Published by Springer Nature
- p. 695-724
Boron Neutron Capture Therapy (BNCT) for Soft Tissue Sarcoma
- 31 May 2025
- Published by Springer Nature
- p. 695-724
Boron Neutron Capture Therapy (BNCT) for Soft Tissue Sarcoma
- 24 April 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 222, 111846
Potential of boron neutron capture therapy (BNCT) for epithelioid sarcoma
- 24 April 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 222, 111846
Potential of boron neutron capture therapy (BNCT) for epithelioid sarcoma
- 11 February 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 219, 111715
Boron neutron capture therapy (BNCT) for left axillary lymph node metastasis of recurrent breast cancer
- 11 February 2025
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 219, 111715
Boron neutron capture therapy (BNCT) for left axillary lymph node metastasis of recurrent breast cancer
- 26 November 2024
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 217, 111603
Potential of boron neutron capture therapy (BNCT) for myxofibrosarcoma
- 26 November 2024
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 217, 111603
Potential of boron neutron capture therapy (BNCT) for myxofibrosarcoma
- Open Access
- 8 January 2022
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 10
Proximal-type epithelioid sarcoma in pubic region expressing L-type amino acid transporter 1: A case report
Proximal-type epithelioid sarcoma is an aggressive malignant soft-tissue neoplasm, a “proximal” variant of epithelioid sarcoma, resistant to multimodal therapy and involved in early tumor-related death. Pertinent treatments are, therefore, continually being explored. A 24-year-old woman with nonmetastatic proximal-type epithelioid sarcoma, originating subcutaneously on the right side of the vulva, underwent surgical resection; the lesion recurred, however, leading to death 3 months after the second surgery. Here described is a case of proximal-type epithelioid sarcoma expressing L-type amino acid transporter 1 (LAT1) that transports essential amino acids and p-borono-L-phenylalanine (BPA)—the chemical compound used in boron neutron capture therapy (BNCT)—and is highly expressed in many malignant tumors. Recently, LAT1 has drawn attention, and relevant treatments have been studied—LAT1 inhibitor and BNCT. LAT1 expression in proximal-type epithelioid sarcoma may lead to cogent treatments for the disease.
- 8 January 2022
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 10
Open AccessProximal-type epithelioid sarcoma in pubic region expressing L-type amino acid transporter 1: A case report
Proximal-type epithelioid sarcoma is an aggressive malignant soft-tissue neoplasm, a “proximal” variant of epithelioid sarcoma, resistant to multimodal therapy and involved in early tumor-related death. Pertinent treatments are, therefore, continually being explored. A 24-year-old woman with nonmetastatic proximal-type epithelioid sarcoma, originating subcutaneously on the right side of the vulva, underwent surgical resection; the lesion recurred, however, leading to death 3 months after the second surgery. Here described is a case of proximal-type epithelioid sarcoma expressing L-type amino acid transporter 1 (LAT1) that transports essential amino acids and p-borono-L-phenylalanine (BPA)—the chemical compound used in boron neutron capture therapy (BNCT)—and is highly expressed in many malignant tumors. Recently, LAT1 has drawn attention, and relevant treatments have been studied—LAT1 inhibitor and BNCT. LAT1 expression in proximal-type epithelioid sarcoma may lead to cogent treatments for the disease.
- 5 July 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-2
Enhancement of thermionic emission and conversion characteristics using polarization- and band-engineered n-type AlGaN cathodes
We observed enhancement of thermionic emission (TE) and conversion (TC) characteristics by controlling spontaneous and piezo polarization and the band diagram of n-type AlGaN/GaN thermionic cathodes. The obtained TE current from N-polarity n-AlGaN films grown on an n-GaN substrate was 0.29 mA at 500 °C in a Cs gas atmosphere in the vacuum gap between the cathode and a stainless steel anode. This TE current was 5.0 times and 1.6 times higher than that from the surface of Ga-polarity n-GaN substrate and that of the Ga-polarity n-AlGaN film on the substrate, respectively.
- 5 July 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-2
Enhancement of thermionic emission and conversion characteristics using polarization- and band-engineered n-type AlGaN cathodes
We observed enhancement of thermionic emission (TE) and conversion (TC) characteristics by controlling spontaneous and piezo polarization and the band diagram of n-type AlGaN/GaN thermionic cathodes. The obtained TE current from N-polarity n-AlGaN films grown on an n-GaN substrate was 0.29 mA at 500 °C in a Cs gas atmosphere in the vacuum gap between the cathode and a stainless steel anode. This TE current was 5.0 times and 1.6 times higher than that from the surface of Ga-polarity n-GaN substrate and that of the Ga-polarity n-AlGaN film on the substrate, respectively.
- Open Access
- 11 November 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (1) , 1
Cathepsin B is highly expressed in pancreatic cancer stem‑like cells and is associated with patients' surgical outcomes
Cancer stem‑like cells (CSLCs) in solid tumors are resistant to conventional chemotherapy and molecularly targeted therapy, which is thought to contribute to cancer recurrence and metastasis. The present study aimed to identify biomarkers for pancreatic CSLCs (P‑CSLCs). Using our previously reported methods, P‑CSLC‑enriched populations were generated from pancreatic cancer cell lines. The protein expression profiles of these populations were compared with those of parental cells using two‑dimensional electrophoresis, tandem mass spectrometry, flow cytometry and immunohistochemistry. Protein expression in surgical specimens was also evaluated for relationships with clinical outcomes. A lysosomal cysteine protease, cathepsin B (CTSB), was significantly upregulated in P‑CSLCs compared with that in the parental cells, as shown using western blotting. Flow cytometry analysis also confirmed that CTSB was more highly expressed on the surface of P‑CSLCs compared with that on parental cells. Moreover, PCLCs had elevated cellular secretions of CTSB compared with the parental cells. Finally, CTSB expression was evaluated in 69 resected tumor specimens, and high expression was associated with the patients' clinicopathological features and surgical outcomes. The present results suggested that CTSB is a biomarker for poor survival in patients with pancreatic cancer, which is possibly associated with P‑CSLCs. This novel biomarker may also have potential as a therapeutic target.
- 11 November 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (1) , 1
Open AccessCathepsin B is highly expressed in pancreatic cancer stem‑like cells and is associated with patients' surgical outcomes
Cancer stem‑like cells (CSLCs) in solid tumors are resistant to conventional chemotherapy and molecularly targeted therapy, which is thought to contribute to cancer recurrence and metastasis. The present study aimed to identify biomarkers for pancreatic CSLCs (P‑CSLCs). Using our previously reported methods, P‑CSLC‑enriched populations were generated from pancreatic cancer cell lines. The protein expression profiles of these populations were compared with those of parental cells using two‑dimensional electrophoresis, tandem mass spectrometry, flow cytometry and immunohistochemistry. Protein expression in surgical specimens was also evaluated for relationships with clinical outcomes. A lysosomal cysteine protease, cathepsin B (CTSB), was significantly upregulated in P‑CSLCs compared with that in the parental cells, as shown using western blotting. Flow cytometry analysis also confirmed that CTSB was more highly expressed on the surface of P‑CSLCs compared with that on parental cells. Moreover, PCLCs had elevated cellular secretions of CTSB compared with the parental cells. Finally, CTSB expression was evaluated in 69 resected tumor specimens, and high expression was associated with the patients' clinicopathological features and surgical outcomes. The present results suggested that CTSB is a biomarker for poor survival in patients with pancreatic cancer, which is possibly associated with P‑CSLCs. This novel biomarker may also have potential as a therapeutic target.
- 18 June 2014
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 118 (26) , 14142-14149
Ambipolar Transport in Phase-Separated Thin Films of p- and n-Type Vanadylporphyrazines with Two-Dimensional Percolation
- 18 June 2014
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry C
- Vol. 118 (26) , 14142-14149
Ambipolar Transport in Phase-Separated Thin Films of p- and n-Type Vanadylporphyrazines with Two-Dimensional Percolation
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 22 (5) , 1579-1583
Tracheobronchial Anomalies in Syndromic Craniosynostosis With 3-Dimensional CT Image and Bronchoscopy
Patients with syndromic craniosynostosis have many problems involving the upper airway, laryngotracheal airway, and tracheobronchial tree. Evaluation of tracheobronchial disorders in syndromic craniosynostosis is very important for accurately diagnosing these problems. We have used three-dimensional computed tomography (CT) imaging of the tracheobronchial tree (three-dimensional tracheal CT imaging) since a multidetector CT was installed in our hospital in 2004. In this study, we assessed the configuration of the tracheobronchial system using three-dimensional tracheal CT imaging and bronchoscopy. During the period from 2004 to 2009, 48 patients with syndromic craniosynostosis underwent surgery at our hospital. Of those, 16 patients required tracheostomy. These syndromic craniosynostosis cases were examined with three-dimensional tracheal CT imaging and bronchoscopy. All CT scans were performed on a multidetector CT (120 kV, 22-120 mA, 0.5 s/slice, 1-mm slice; Aquilion; Toshiba Co, Tokyo, Japan) without respiratory suppression. All 16 study patients presented with severe stenosis of the upper airway on bronchoscopic examination. Seven were confirmed to have abnormalities by both bronchoscopy and three-dimensional tracheal CT imaging. Four were confirmed to have abnormalities on either bronchoscopy or three-dimensional tracheal CT imaging, whereas 5 patients were apparently free of abnormalities as determined by both modalities. In conclusion, it was possible to accurately assess the configuration of the tracheobronchial system using both three-dimensional tracheal CT imaging and bronchoscopy. Our results suggest these examinations to be very useful for assessing the optimal timing of decannulation and respiratory function prognosis.
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 22 (5) , 1579-1583
Tracheobronchial Anomalies in Syndromic Craniosynostosis With 3-Dimensional CT Image and Bronchoscopy
Patients with syndromic craniosynostosis have many problems involving the upper airway, laryngotracheal airway, and tracheobronchial tree. Evaluation of tracheobronchial disorders in syndromic craniosynostosis is very important for accurately diagnosing these problems. We have used three-dimensional computed tomography (CT) imaging of the tracheobronchial tree (three-dimensional tracheal CT imaging) since a multidetector CT was installed in our hospital in 2004. In this study, we assessed the configuration of the tracheobronchial system using three-dimensional tracheal CT imaging and bronchoscopy. During the period from 2004 to 2009, 48 patients with syndromic craniosynostosis underwent surgery at our hospital. Of those, 16 patients required tracheostomy. These syndromic craniosynostosis cases were examined with three-dimensional tracheal CT imaging and bronchoscopy. All CT scans were performed on a multidetector CT (120 kV, 22-120 mA, 0.5 s/slice, 1-mm slice; Aquilion; Toshiba Co, Tokyo, Japan) without respiratory suppression. All 16 study patients presented with severe stenosis of the upper airway on bronchoscopic examination. Seven were confirmed to have abnormalities by both bronchoscopy and three-dimensional tracheal CT imaging. Four were confirmed to have abnormalities on either bronchoscopy or three-dimensional tracheal CT imaging, whereas 5 patients were apparently free of abnormalities as determined by both modalities. In conclusion, it was possible to accurately assess the configuration of the tracheobronchial system using both three-dimensional tracheal CT imaging and bronchoscopy. Our results suggest these examinations to be very useful for assessing the optimal timing of decannulation and respiratory function prognosis.
- 1 April 2011
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of neurosurgery. Pediatrics
- Vol. 7 (4) , 345-350
Retrospective assessment of the dismasking flap procedure as a craniofacial approach
Object: In 1997 the authors presented the case of a 3-year-old girl who underwent complete resection of a huge tumor via a new technique using a dismasking flap. Since that report, 14 patients have undergone surgery using this technique. There have been few reports on long-term follow-up after a craniofacial surgical approach and reconstruction of a huge tissue defect. The authors report details of this procedure based on these cases, including long-term follow-up in the original case. Methods: The dismasking flap is a cranioorbitofacial degloving method that uses a circumpalpebral approach with or without piriform margin incisions and presents a wide surgical field under direct vision. Fourteen patients have undergone surgery using the dismasking flap technique. These patients had multiple craniofacial bone fractures (3 cases) and malignant or premalignant craniofacial tumors (11 cases). Patients ranged in age from 3 to 62 years old. The longest follow-up period was 15 years. The results of these cases are reported regarding changes in the facial bones and soft tissues with growth, the various pathologies involved, and complications. Results: Complications using this approach were lagophthalmos with ectropion of the lower eyelid, disturbance of the superior orbital nerve, disturbance of the inferior orbital nerve, maxillary hypoplasia, and blepharoptosis. In all affected patients these complications were almost always temporary. In 2 of the 14 cases, a repair operation for lagophthalmos was necessary, while others showed spontaneous improvement approximately 6 months to a year after the procedure. In the case with the longest follow-up duration, the patient's nose is asymmetrical, especially the alar portion, due to hypoplasia of the grafted bone and/or the fixation with titanium miniplates. Conclusions: This flap is very useful for en bloc resection of huge skull base tumors, multiple craniofacial bone fractures, and as a lateral approach to a deep portion of the middle cranial base. Careful attention is necessary, however, because one may encounter unexpected complications if one does not ensure adequate protection of the perioperative flap. Meticulous postoperative management is also essential.
- 1 April 2011
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of neurosurgery. Pediatrics
- Vol. 7 (4) , 345-350
Retrospective assessment of the dismasking flap procedure as a craniofacial approach
Object: In 1997 the authors presented the case of a 3-year-old girl who underwent complete resection of a huge tumor via a new technique using a dismasking flap. Since that report, 14 patients have undergone surgery using this technique. There have been few reports on long-term follow-up after a craniofacial surgical approach and reconstruction of a huge tissue defect. The authors report details of this procedure based on these cases, including long-term follow-up in the original case. Methods: The dismasking flap is a cranioorbitofacial degloving method that uses a circumpalpebral approach with or without piriform margin incisions and presents a wide surgical field under direct vision. Fourteen patients have undergone surgery using the dismasking flap technique. These patients had multiple craniofacial bone fractures (3 cases) and malignant or premalignant craniofacial tumors (11 cases). Patients ranged in age from 3 to 62 years old. The longest follow-up period was 15 years. The results of these cases are reported regarding changes in the facial bones and soft tissues with growth, the various pathologies involved, and complications. Results: Complications using this approach were lagophthalmos with ectropion of the lower eyelid, disturbance of the superior orbital nerve, disturbance of the inferior orbital nerve, maxillary hypoplasia, and blepharoptosis. In all affected patients these complications were almost always temporary. In 2 of the 14 cases, a repair operation for lagophthalmos was necessary, while others showed spontaneous improvement approximately 6 months to a year after the procedure. In the case with the longest follow-up duration, the patient's nose is asymmetrical, especially the alar portion, due to hypoplasia of the grafted bone and/or the fixation with titanium miniplates. Conclusions: This flap is very useful for en bloc resection of huge skull base tumors, multiple craniofacial bone fractures, and as a lateral approach to a deep portion of the middle cranial base. Careful attention is necessary, however, because one may encounter unexpected complications if one does not ensure adequate protection of the perioperative flap. Meticulous postoperative management is also essential.